Preclinical Characterization of an Antibody-Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1-Positive Cells.
Animals
Antibodies, Monoclonal
/ chemistry
Antineoplastic Agents
/ chemistry
Apoptosis
Benzodiazepines
/ chemistry
Cell Proliferation
Drug Evaluation, Preclinical
Female
Humans
Immunoconjugates
/ chemistry
Macaca fascicularis
Membrane Proteins
/ antagonists & inhibitors
Mice
Mice, Inbred NOD
Mice, SCID
Microfilament Proteins
/ antagonists & inhibitors
Multiple Myeloma
/ drug therapy
Pyrroles
/ chemistry
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
06
05
2019
revised:
21
11
2019
accepted:
08
05
2020
pubmed:
15
5
2020
medline:
3
6
2021
entrez:
15
5
2020
Statut:
ppublish
Résumé
Multiple myeloma is a hematologic cancer that disrupts normal bone marrow function and has multiple lines of therapeutic options, but is incurable as patients ultimately relapse. We developed a novel antibody-drug conjugate (ADC) targeting CS-1, a protein that is highly expressed on multiple myeloma tumor cells. The anti-CS-1 mAb specifically bound to cells expressing CS-1 and, when conjugated to a cytotoxic pyrrolobenzodiazepine payload, reduced the viability of multiple myeloma cell lines
Identifiants
pubmed: 32404408
pii: 1535-7163.MCT-19-0482
doi: 10.1158/1535-7163.MCT-19-0482
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents
0
ITPRID2 protein, human
0
Immunoconjugates
0
Membrane Proteins
0
Microfilament Proteins
0
Pyrroles
0
pyrrolo(2,1-c)(1,4)benzodiazepine
0
Benzodiazepines
12794-10-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1649-1659Informations de copyright
©2020 American Association for Cancer Research.